Cargando…
Combined Antiseizure Efficacy of Cannabidiol and Clonazepam in a Conditional Mouse Model of Dravet Syndrome
Dravet Syndrome (DS) is a severe childhood epilepsy caused by heterozygous loss-of-function mutations in the SCN1A gene encoding brain type-I voltage-gated sodium channel Na(v)1.1. DS is a devastating disease that typically begins at six to nine months of age. Symptoms include recurrent intractable...
Autores principales: | Chuang, Shu-Hui, Westenbroek, Ruth E., Stella, Nephi, Catterall, William A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8301289/ https://www.ncbi.nlm.nih.gov/pubmed/34308420 http://dx.doi.org/10.33696/neurol.2.040 |
Ejemplares similares
-
The serine hydrolase ABHD6 controls survival and thermally induced seizures in a mouse model of Dravet syndrome
por: Westenbroek, Ruth, et al.
Publicado: (2023) -
Efficacy and safety of adjunctive antiseizure medications for dravet syndrome: A systematic review and network meta-analysis
por: Wu, Jianhua, et al.
Publicado: (2022) -
A retrospective review of changes and challenges in the use of antiseizure medicines in Dravet syndrome in Norway
por: Heger, Katrine, et al.
Publicado: (2020) -
Cannabidiol for epilepsy (Lennox-Gastaut syndrome, Dravet syndrome)
Publicado: (2020) -
Channelopathy of Dravet Syndrome and Potential Neuroprotective Effects of Cannabidiol
por: Xu, Changqing, et al.
Publicado: (2021)